Hebei Medical University Fourth Hospital

This study is testing whether adding two new immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy works better for advanced esophageal cancer that has returned or spread. It will involve about 25 adults who haven't had prior treatment for their advanced can…

This study is testing two different combinations of oral medications given before surgery (neoadjuvant therapy) for early-stage breast cancer that is hormone-sensitive. It aims to see if adding a third drug (entinostat) to a standard two-drug combo (dalpiciclib and letrozole) is …

This study is testing whether a drug called trilaciclib can protect patients' bone marrow from damage during chemotherapy for solid tumors. Researchers will enroll 100 patients to see if the drug reduces severe blood cell drops, which are common and dangerous side effects of canc…

This study is comparing two different chemotherapy combinations for women with advanced triple-negative breast cancer, a particularly aggressive form of the disease. Researchers want to see which combination works better at controlling cancer growth and has fewer side effects. Th…

This study is testing if a drug called adebrelizumab can help prevent esophageal cancer from returning after surgery. It will involve 142 adults who have recently had surgery to remove their cancer but have not yet received any other post-surgery treatment. Researchers will compa…

This study is comparing two ways to give radiation during breast-conserving surgery for early breast cancer. It will follow 620 women aged 55+ to see which method better prevents cancer from returning locally and causes fewer complications. One group gets a single dose of radiati…

This study is testing a new combination of four drugs for people with an aggressive type of advanced stomach or gastroesophageal cancer that has continued to grow despite initial treatment with immunotherapy and chemotherapy. The goal is to see if this new drug mix can shrink tum…

This study observes how well the drug dalpiciclib works for people with advanced hormone-positive breast cancer in real-world settings. Researchers will follow 420 patients whose doctors have chosen to use dalpiciclib as part of their treatment. The study tracks how long the canc…

This study is testing whether a new drug combination (dalpiciclib plus hormone therapy) works as well as standard chemotherapy for shrinking certain breast cancers before surgery. It will involve 144 postmenopausal women with ER-positive, HER2-negative breast cancer. The main goa…

This study is testing whether adding the drug bevacizumab to standard chemotherapy helps shrink tumors more effectively before surgery in people with early or locally advanced HER2-negative breast cancer. The goal is to see if this combination leads to better outcomes, like compl…

This study is testing which of two chemotherapy combinations works better to shrink tumors before surgery for triple-negative breast cancer, an aggressive type. Researchers will compare nab-paclitaxel with carboplatin versus nab-paclitaxel with epirubicin in 520 women. The goal i…

This study aims to see how well and safely a specific injection works to prevent neutropenia, a dangerous drop in infection-fighting white blood cells, in real-world cancer patients. It will observe about 200 adults with solid tumors who are receiving treatments like chemotherapy…

This study aims to build an early warning system to predict when cancer patients receiving immunotherapy might develop serious organ damage. Researchers will analyze blood samples and health data from 2000 patients to identify patterns that signal risk before damage occurs. The g…